Placebo | AZD9164 | ||||
---|---|---|---|---|---|
GMAD, healthy subjects | n = 9 | 400 μg | 1000 μg | 2800 μg | Total (%) |
n = 6 | n = 6 | n = 6 | n = 27 | ||
Any AEa | 8 (88.9) | 5 (83.3) | 6 (100) | 6 (100) | 25 (92.6) |
SAEsa | 1(11.1) | 0 (0) | 0 (0) | 0 (0) | 1 (3.7) |
DAEsa | 2 (22.2) | 0 (0) | 0 (0) | 0 (0) | 2 (7.4) |
Total number of AEs | 31 | 7 | 18 | 15 | 71 |
JMAD, healthy subjects | n = 6 | 400 μg | 1000 μg | Total (%) | |
n = 6 | n = 6 | n = 18 | |||
Any AEa | 3 (50.0) | 6 (100.0) | 4 (66.7) | 13 (72.2) | |
SAEsa | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
DAEsa | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
Total number of AEs | 3 | 10 | 7 | 20 | |
GMAD, COPD patients | n = 1 | n = 3 | n = 4 | ||
Any AEa | 1 (100) | 3 (100) | 4 (100) | ||
SAEsa | 0 (0) | 0 (0) | 0 (0) | ||
DAEsa | 0 (0) | 1 (33.3) | 1 (25.0) | ||
Total number of AEs | 1 | 8 | 9 |